Royal Sense [ROYAL] vs Entero Healthcare [ENTERO] Detailed Stock Comparison
Royal Sense
BSE
Loading...
Entero Healthcare
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Royal Sense wins in 11 metrics, Entero Healthcare wins in 6 metrics, with 0 ties. Royal Sense appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Royal Sense | Entero Healthcare | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.33 | 54.82 | Royal Sense |
| Price-to-Book Ratio | 3.62 | 3.01 | Entero Healthcare |
| Debt-to-Equity Ratio | 11.74 | 21.76 | Royal Sense |
| EV/EBITDA | 10.41 | 29.36 | Royal Sense |
| Profit Margin (TTM) | 10.26% | 1.90% | Royal Sense |
| Operating Margin (TTM) | 14.32% | 2.94% | Royal Sense |
| EBITDA Margin (TTM) | 14.32% | 2.94% | Royal Sense |
| Return on Equity | 27.55% | 5.36% | Royal Sense |
| Return on Assets (TTM) | 19.67% | 3.51% | Royal Sense |
| Free Cash Flow (TTM) | $-4.77M | $-881.78M | Royal Sense |
| 1-Year Return | 41.38% | 4.72% | Royal Sense |
| Price-to-Sales Ratio (TTM) | 1.78 | 0.96 | Entero Healthcare |
| Enterprise Value | $924.84M | $57.20B | Entero Healthcare |
| EV/Revenue Ratio | 1.50 | 1.06 | Entero Healthcare |
| Gross Profit Margin (TTM) | 15.60% | 9.77% | Royal Sense |
| Revenue per Share (TTM) | $126 | $1,242 | Entero Healthcare |
| Earnings per Share (Diluted) | $11.83 | $21.78 | Entero Healthcare |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Royal Sense vs Entero Healthcare Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Royal Sense | -0.97% | -0.97% | -14.37% | -5.51% | -22.64% | -33.01% |
| Entero Healthcare | -8.05% | -1.13% | 5.00% | -4.26% | -7.68% | -10.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Royal Sense | 41.38% | 83.91% | 83.91% | 83.91% | 83.91% | 83.91% |
| Entero Healthcare | 4.72% | 12.11% | 12.11% | 12.11% | 12.11% | 12.11% |
Performance & Financial Health Analysis: Royal Sense vs Entero Healthcare
| Metric | ROYAL | ENTERO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.10B | ₹51.95B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 2,700 | 68,835 |
| 90 Day Avg. Volume | 2,783 | 73,432 |
| Last Close | ₹205.00 | ₹1,185.10 |
| 52 Week Range | ₹133.00 - ₹316.05 | ₹1,080.00 - ₹1,584.25 |
| % from 52W High | -35.14% | -25.19% |
| All-Time High | ₹316.05 (Dec 30, 2024) | ₹1,584.25 (Nov 04, 2024) |
| % from All-Time High | -35.14% | -25.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 7.13% | 0.28% |
| Quarterly Earnings Growth | 7.93% | 0.38% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.02% |
| Operating Margin (TTM) | 0.14% | 0.03% |
| Return on Equity (TTM) | 0.28% | 0.05% |
| Debt to Equity (MRQ) | 11.74 | 21.76 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹56.59 | ₹396.70 |
| Cash per Share (MRQ) | ₹22.95 | ₹73.09 |
| Operating Cash Flow (TTM) | ₹11.39M | ₹-1,784,970,000 |
| Levered Free Cash Flow (TTM) | ₹-32,393,500 | ₹948.20M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Royal Sense vs Entero Healthcare
| Metric | ROYAL | ENTERO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.33 | 54.82 |
| Forward P/E | N/A | 22.58 |
| PEG Ratio | N/A | N/A |
| Price to Sales (TTM) | 1.78 | 0.96 |
| Price to Book (MRQ) | 3.62 | 3.01 |
| Market Capitalization | ||
| Market Capitalization | ₹1.10B | ₹51.95B |
| Enterprise Value | ₹924.84M | ₹57.20B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.50 | 1.06 |
| Enterprise to EBITDA | 10.41 | 29.36 |
| Risk & Other Metrics | ||
| Beta | N/A | N/A |
| Book Value per Share (MRQ) | ₹56.59 | ₹396.70 |
Financial Statements Comparison: Royal Sense vs Entero Healthcare
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ROYAL | ENTERO |
|---|---|---|
| Revenue/Sales | ₹33.92M | ₹13.39B |
| Cost of Goods Sold | ₹28.63M | ₹12.08B |
| Gross Profit | ₹5.29M | ₹1.31B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.60M | ₹404.21M |
| EBITDA | ₹2.69M | ₹561.07M |
| Pre-Tax Income | ₹2.65M | ₹371.25M |
| Income Tax | ₹690,000 | ₹58.02M |
| Net Income (Profit) | ₹1.96M | ₹314.23M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ROYAL | ENTERO |
|---|---|---|
| Cash & Equivalents | ₹30.67M | ₹2.29B |
| Total Current Assets | ₹223.51M | ₹20.76B |
| Total Current Liabilities | ₹34.38M | ₹8.45B |
| Long-Term Debt | N/A | ₹670.18M |
| Total Shareholders Equity | ₹205.89M | ₹17.70B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | ₹1.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ROYAL | ENTERO |
|---|---|---|
| Operating Cash Flow | ₹50.91M | N/A |
| Capital Expenditures | ₹233,000 | N/A |
| Free Cash Flow | ₹26.63M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ROYAL | ENTERO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,700 | 68,835 |
| Average Daily Volume (90 Day) | 2,783 | 73,432 |
| Shares Outstanding | 4.97M | 43.51M |
| Float Shares | 1.48M | 13.00M |
| % Held by Insiders | 0.65% | 0.63% |
| % Held by Institutions | 0.00% | 0.23% |
Dividend Analysis & Yield Comparison: Royal Sense vs Entero Healthcare
| Metric | ROYAL | ENTERO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |